NCT04469556 2026-02-20
PASS-01
University Health Network, Toronto
Phase 2 Completed
Clinical Trials
29 trialsNCT07208539 2025-10-06
ZSPAC-14
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT03563248 2025-10-01
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05132504 2025-07-18
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Baylor College of Medicine
Phase 2 Recruiting
NCT04594772 2025-07-02
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT04084496 2025-05-30
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Sun Yat-sen University
Phase 2 Recruiting
NCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT02352337 2024-07-10
PANOPTIMOX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT04589234 2024-04-24
Saltikva for Metastatic Pancreatic Cancer
Salspera LLC
Phase 2 Active not recruiting
NCT02128100 2024-03-05
BCC-RAD-13
University of Louisville
Phase 2 Completed
NCT03291899 2024-01-17
FBI-TRAC
King Faisal Specialist Hospital & Research Center
Phase 2 Terminated
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT05868317 2023-05-22
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
Phase 2 Unknown
NCT02178709 2022-04-19
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
Phase 2 Completed
NCT01676259 2021-07-02
PROTACT
Silenseed Ltd
Phase 2 Unknown
NCT04398927 2021-02-04
Systemic Chemotherapy Plus PD-1 for Metastasis ICC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03042780 2020-11-27
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03825861 2020-11-10
FOLFIRINOX
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT04611724 2020-11-02
A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer
Asan Medical Center
Phase 2 Unknown
NCT01821729 2020-09-25
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT02717091 2020-09-10
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Nagoya University
Phase 2 Unknown
NCT01896869 2020-05-19
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02456714 2020-03-10
4CC
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
NCT04130399 2019-10-17
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Indiana University
Phase 2 Withdrawn
NCT03812783 2019-01-23
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
Sun Yat-sen University
Phase 2 Unknown
NCT02862015 2017-10-31
Oncothermia
Seoul National University Hospital
Phase 2 Unknown
NCT01688336 2017-10-06
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01523457 2017-08-30
FOLFIRINOX
Yale University
Phase 2 Completed
NCT02243007 2017-05-16
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Terminated